X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nivolumab (1470) 1470
index medicus (1020) 1020
humans (959) 959
oncology (916) 916
immunotherapy (888) 888
ipilimumab (688) 688
melanoma (656) 656
cancer (563) 563
pembrolizumab (549) 549
male (458) 458
chemotherapy (441) 441
metastasis (400) 400
female (395) 395
middle aged (381) 381
aged (366) 366
care and treatment (354) 354
patients (352) 352
antibodies, monoclonal - adverse effects (338) 338
lung cancer (332) 332
cancer therapies (328) 328
open-label (319) 319
docetaxel (296) 296
antibodies, monoclonal - therapeutic use (292) 292
immunology (286) 286
safety (271) 271
metastatic melanoma (269) 269
programmed cell death 1 receptor - antagonists & inhibitors (258) 258
pd-1 (256) 256
melanoma - drug therapy (250) 250
tumors (242) 242
antineoplastic agents - adverse effects (238) 238
antineoplastic agents - therapeutic use (234) 234
treatment outcome (225) 225
survival (224) 224
clinical trials (219) 219
antineoplastic agents, immunological - adverse effects (218) 218
adult (216) 216
therapy (216) 216
adverse events (214) 214
immune checkpoint (212) 212
lung neoplasms - drug therapy (207) 207
research (200) 200
apoptosis (198) 198
blockade (192) 192
advanced melanoma (182) 182
neoplasms. tumors. oncology. including cancer and carcinogens (182) 182
cell lung-cancer (173) 173
lymphocytes (173) 173
immune checkpoint inhibitors (170) 170
drug therapy (168) 168
lung cancer, non-small cell (165) 165
immunotherapy - methods (159) 159
aged, 80 and over (158) 158
nivolumab - adverse effects (156) 156
complications and side effects (150) 150
carcinoma, non-small-cell lung - drug therapy (147) 147
multicenter (146) 146
ligands (143) 143
antineoplastic agents, immunological - therapeutic use (142) 142
pharmacology & pharmacy (142) 142
analysis (141) 141
case report (139) 139
pd-1 protein (139) 139
cytotoxicity (137) 137
anti-pd-1 (131) 131
antigens (130) 130
antibodies, monoclonal, humanized - adverse effects (129) 129
cell death (128) 128
programmed cell death 1 receptor - immunology (128) 128
skin neoplasms - drug therapy (124) 124
untreated melanoma (124) 124
immunotherapy - adverse effects (122) 122
dermatology (121) 121
development and progression (121) 121
toxicity (121) 121
usage (121) 121
medical prognosis (119) 119
mutation (118) 118
studies (118) 118
immune system (117) 117
medicine, research & experimental (114) 114
melanoma - pathology (114) 114
neoplasms - drug therapy (114) 114
pd-l1 (114) 114
antibodies (112) 112
antibodies, monoclonal - administration & dosage (110) 110
health aspects (110) 110
double-blind (109) 109
immune checkpoint inhibitor (109) 109
non-small cell lung cancer (109) 109
metastases (108) 108
biomarkers (107) 107
medical research (107) 107
medicine, general & internal (107) 107
review (104) 104
antineoplastic combined chemotherapy protocols - therapeutic use (103) 103
ctla-4 antigen - antagonists & inhibitors (103) 103
immune-related adverse events (103) 103
immunoglobulins (102) 102
lung neoplasms - pathology (102) 102
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1709) 1709
French (17) 17
German (12) 12
Japanese (7) 7
Chinese (3) 3
Spanish (3) 3
Russian (2) 2
Danish (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 2, pp. 221 - 236
The last decade has spawned an exciting new era of oncotherapy in dermatology, including the development of targeted therapies for metastatic melanoma and... 
Lambrolizumab | RAS | Ipilimumab | Panniculitis | Verrucal keratosis | Autoimmune dermopathies | PI3K-AKT-mTOR pathway | Seborrheic dermatitis | Temsirolimus | Pruritus | Dermatitis | Keratoacanthoma | Autoimmune adverse effects | Vitiligo | RAF inhibitors | Immunotherapy | Immune-related toxicities | mTOR inhibitor | B-RAF | Everolimus | PI3 kinase inhibitor | Squamous cell carcinoma | Dysgeusia | Selumetinib | Dual inhibitor | MEK inhibitors | Dabrafenib | Rapamycin | PD-1 inhibitor | Trametinib | Keratotic squamoproliferative lesion | Vemurafenib | AKT inhibitor | Loss of taste | Nivolumab | MAP kinase pathway | Hedgehog signaling pathway | Taste alteration | Vismodegib | Hair loss | Keratosis pilaris | pruritus | ADVANCED CANCER | lambrolizumab | nivolumab | dysgeusia | RENAL-CELL CARCINOMA | METASTATIC MELANOMA | ipilimumab | autoimmune adverse effects | AZD6244 ARRY-142886 | MAMMALIAN TARGET | vitiligo | TASTE PAPILLA DEVELOPMENT | BRAF INHIBITORS | vismodegib | hair loss | hedgehog signaling pathway | panniculitis | keratotic squamoproliferative lesion | keratoacanthoma | taste alteration | seborrheic dermatitis | VEMURAFENIB TREATMENT | DERMATOLOGY | trametinib | keratosis pilaris | everolimus | dermatitis | immunotherapy | autoimmune dermopathies | dabrafenib | verrucal keratosis | ADVANCED SOLID TUMORS | vemurafenib | selumetinib | loss of taste | temsirolimus | immune-related toxicities | dual inhibitor | rapamycin | squamous cell carcinoma | Drug Eruptions - etiology | Molecular Targeted Therapy - adverse effects | Skin Neoplasms - drug therapy | Photosensitivity Disorders - chemically induced | Humans | Carcinoma, Squamous Cell - chemically induced | Drug Eruptions - therapy | Skin Neoplasms - chemically induced | Photosensitivity Disorders - therapy | Immunotherapy - adverse effects | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Panniculitis - chemically induced | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Drug Eruptions - diagnosis | Alopecia - chemically induced | Mitogen-Activated Protein Kinases - drug effects | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus
Journal Article
NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 09/2019, Volume 16, Issue 9, pp. 563 - 580
Journal Article
Dermatologic Therapy, ISSN 1396-0296, 09/2019, Volume 32, Issue 5, pp. e13074 - n/a
Checkpoint inhibitors are a new class of drugs that enhance the immune system's intrinsic ability to destroy tumor cells by blocking signaling through the... 
nivolumab | neutrophilic dermatosis | ipilimumab
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 2, pp. 206 - 207
Journal Article
Current Opinion in Oncology, ISSN 1040-8746, 03/2017, Volume 29, Issue 2, pp. 136 - 144
Journal Article
Journal of Thoracic Disease, ISSN 2072-1439, 02/2018, Volume 10, Issue Suppl 3, pp. S480 - S489
Immunotherapy has revolutionized the field of oncology. By inhibiting the cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death-1 (PD-1)... 
Checkpoint inhibitors | Immunotherapy | Toxicities | MANAGEMENT | STAGE-III MELANOMA | toxicities | REVERSIBLE ENCEPHALOPATHY SYNDROME | TROPONIN-I | METASTATIC MELANOMA | CANCER-PATIENTS | RESPIRATORY SYSTEM | immunotherapy | DOUBLE-BLIND | INHIBITORS | NIVOLUMAB | IPILIMUMAB | Review
Journal Article
Cell Research, ISSN 1001-0602, 04/2018, Volume 28, Issue 4, pp. 433 - 447
Anti-CTLA-4 monoclonal antibodies (mAbs) confer a cancer immunotherapeutic effect (CITE) but cause severe immunotherapy-related adverse events (irAE).... 
METASTATIC MELANOMA | LUNG-CANCER | IMMUNITY | AUTOIMMUNITY | REGULATORY T-CELLS | CHECKPOINT | ANTITUMOR-ACTIVITY | BLOCKADE | NIVOLUMAB PLUS IPILIMUMAB | CHEMOTHERAPY | CELL BIOLOGY | Immunoglobulins | PD-1 protein | Effector cells | T cell receptors | Activation | Lymphocytes T | B7 antigen | CTLA-4 protein | Cell activation | Immunology | Lymphocytes | Immunotherapy | Reagents | Monoclonal antibodies | Mice | Safety | Cancer
Journal Article
RADIOLOGE, ISSN 0033-832X, 10/2017, Volume 57, Issue 10, pp. 840 - 849
Background. The increasing use of immunotherapy in oncology increases the need for radiologic evaluation of frequent and severe immune-related adverse events.... 
DIAGNOSIS | EVENTS | MANAGEMENT | IMMUNE-CHECKPOINT INHIBITORS | Immune checkpoint inhibitors | CANCER-THERAPY | Magnetic resonance tomography | METASTATIC MELANOMA | TOXICITIES | Computed tomography | Immunerelated adverse events | PNEUMONITIS | Imaging results | IPILIMUMAB-INDUCED HYPOPHYSITIS | NIVOLUMAB | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
American Journal of Nephrology, ISSN 0250-8095, 02/2017, Volume 45, Issue 2, pp. 160 - 169
Journal Article
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, ISSN 1078-1552, 07/2019, Volume 25, Issue 5, pp. 1275 - 1281
Immunotherapy treatments in oncology have garnered much attention and use throughout the past several years. With increased use and new approvals in many... 
Checkpoint inhibitors | MANAGEMENT | EVENTS | immune-mediated adverse effects | immune-related adverse effects | METHOTREXATE | CALCINEURIN INHIBITORS | VERSUS-HOST-DISEASE | CHECKPOINT BLOCKADE | TOXICITIES | ONCOLOGY | immunotherapy | PHARMACOLOGY & PHARMACY | NIVOLUMAB | IPILIMUMAB
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article